Gavriel Barabash - Clal Biotechnology Director

CBI Stock   45.00  0.80  1.81%   

Director

Dr. Gavriel Barabash serves as Director at Clal Biotechnology Industries Ltd. since September 25, 2003 since 2003.
Age 62
Tenure 21 years
Professional MarksPh.D
Phone972 3 612 1616
Webhttps://www.cbi.co.il
Barabash has a Doctorate of Medicine degree in Medicine from The Hebrew University of Jerusalem.

Clal Biotechnology Management Efficiency

The company has return on total asset (ROA) of (0.1194) % which means that it has lost $0.1194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4545) %, meaning that it generated substantial loss on money invested by shareholders. Clal Biotechnology's management efficiency ratios could be used to measure how well Clal Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 52.28 M in total debt with debt to equity ratio (D/E) of 6.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Clal Biotechnology has a current ratio of 3.6, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Clal Biotechnology until it has trouble settling it off, either with new capital or with free cash flow. So, Clal Biotechnology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Clal Biotechnology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Clal to invest in growth at high rates of return. When we think about Clal Biotechnology's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 11 records

DIRECTOR Age

Eran PerryCompugen
N/A
Yair AharonowitzCompugen
73
Ruth ArnonCompugen
86
Joshua ShemerCompugen
63
Dov HershbergCompugen
74
Kinneret SavitskyCompugen
50
Sanford ZweifachCompugen
60
Michal PremingerCompugen
N/A
Arie OvadiaCompugen
67
Gilead HalevyCompugen
51
JeanPierre BizzariCompugen
64
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. Clal Biotechnology Industries (CBI) is traded on Tel Aviv Stock Exchange in Israel and employs 21 people.

Management Performance

Clal Biotechnology Leadership Team

Elected by the shareholders, the Clal Biotechnology's board of directors comprises two types of representatives: Clal Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clal. The board's role is to monitor Clal Biotechnology's management team and ensure that shareholders' interests are well served. Clal Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clal Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ofer Goldberg, VP
Iris Sadeh, Accountant
Liat Nissan, Controller
Sigalia Heifetz, Director
Shmuel Rubinstein, External Director
Tomer Babai, Director
Dafna Gruber, Director
Aharon Schwartz, Director
Gavriel Barabash, Director
Isaac Kohlberg, Director
Nofar Malovani, Director
Arnon MD, Medical Director
Pr MD, VP MediWound
Assaf Segal, Acting Officer
Ofer Gonen, Vice President
Avraham Fischer, Chairman of the Board
Yuval Yanai, External Director
Julian Adams, President Chief Scientific Officer
Orit Lidor, VP and General Counsel
Shiran Manor, Co Sec
Etty Kliger, VP MediWound

Clal Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Clal Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Clal Biotechnology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Clal Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Clal Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Moving together with Clal Stock

  0.75GPGB GP Global PowerPairCorr

Moving against Clal Stock

  0.44BOLT BioLight Life SciencesPairCorr
  0.44INFR InfimerPairCorr
The ability to find closely correlated positions to Clal Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Clal Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Clal Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Clal Biotechnology Industries to buy it.
The correlation of Clal Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Clal Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Clal Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Clal Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clal Biotechnology Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Clal Stock analysis

When running Clal Biotechnology's price analysis, check to measure Clal Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clal Biotechnology is operating at the current time. Most of Clal Biotechnology's value examination focuses on studying past and present price action to predict the probability of Clal Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clal Biotechnology's price. Additionally, you may evaluate how the addition of Clal Biotechnology to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Bonds Directory
Find actively traded corporate debentures issued by US companies
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Please note, there is a significant difference between Clal Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clal Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clal Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.